Characteristic | Categories | Frequency [column %] | ||
---|---|---|---|---|
 |  | Cross-section 1 (n = 86) | Cross-section 2 (n = 146) | Total (n = 232) |
Gender | Male | 16 [18.6] | 38 [26.0] | 54 [23.3] |
Female | 70 [81.4] | 108 [74.0] | 178 [76.7] | |
*Age (years) | Median | 36.5 | 39.3 | 38.5 |
[IQR] | [31.4 – 44.4] | [32.7 – 46.1] | [32.2 – 44.8] | |
Age group (years) | 15.0 – 34.9 | 33 [38.4] | 47 [32.2] | 80 [34.5] |
≥ 35.0 | 53 [61.6] | 99 [67.8] | 152 [65.5] | |
Marital status | Single | 10 [11.6] | 9 [6.2] | 19 [8.2] |
Married (monogamous/polygamous) | 52 [60.5] | 80 [54.8] | 132 [56.9] | |
Separated/divorced/widowed | 24 [27.9] | 57 [39.0] | 81 [34.9] | |
Religion | Christian | 64 [74.4] | 88 [60.3] | 152 [65.5] |
Muslim | 13 [15.1] | 28 [19.2] | 41 [17.7] | |
Others | 9 [10.5] | 30 [20.6] | 39 [16.8] | |
Education status | Primary schooling/less | 68 [79.1] | 119 [81.5] | 187 [80.6] |
Secondary/higher | 18 [20.9] | 27 [18.5] | 45 [19.4] | |
*Distance (km) | Median | 7.8 | 7.8 | 7.8 |
[IQR] | [2.2 – 21.0] | [2.2 – 13.4] | [2.2 – 15.7] | |
Group distance (km) | < 10.0 | 50 [58.1] | 98 [67.1] | 148 [63.8] |
≥ 10.0 | 36 [41.9] | 48 [32.9] | 84 [36.2] | |
Starting 1 st line regimen | Zidovudine based | 37 [43.0] | 81 [55.5] | 118 [50.9] |
Stavudine based | 49 [57.0] | 65 [44.5] | 114 [49.1] | |
*Baseline WHO staging | I/II | 41 [47.7] | 90 [61.6] | 131 [56.5] |
III/IV | 44 [51.2] | 56 [38.4] | 100 [43.1] | |
Missing | 1 [0.0] | 0 [0.0] | 1 [0.4] | |
*Baseline BMI (Kg/m 2 ) | Median | 19.3 | 19.0 | 19.3 |
(IQR) | [17.6 – 20.7] | [17.3 – 21.1] | [17.4 – 21.1] | |
Baseline BMI groups (Kg/m 2 ) | < 18.5 | 32 [37.2] | 63 [43.2] | 95 [41.0] |
≥ 18.5 | 53 [61.6] | 83 [56.9] | 136 [58.6] | |
Missing | 1 [1.2] | 0 [0.0] | 1 [0.4] | |
*Baseline CD4 count (cells/uL) | Median | 124 | 126 | 124 |
(IQR) | [61 – 197] | [35–193] | [40–196] | |
Baseline CD4 groups (cells/uL) | < 100 | 33 [38.4] | 63 [43.2] | 96 [41.4] |
≥ 100 | 51 [59.3] | 83 [56.9] | 134 [57.8] | |
Missing | 2 [2.3] | 0 [0.0] | 2 [0.9] | |
*Duration on ART (months) | Median | 13.3 | 15.0 | 13.9 |
[IQR] | [9.0 – 16.1] | [10.8 – 20.3] | [10.0 – 18.3] | |
Group duration on ART (months) | <12.0 | 32 [37.2] | 49 [33.6] | 81 [34.9] |
≥ 12.0 | 54 [62.8] | 97 [66.4] | 151 [65.1] | |
Drug substitution | No | 68 [79.1] | 100 [68.5] | 168 [72.4] |
Yes | 18 [20.9] | 46 [31.5] | 64 [27.6] | |
WHO staging | Stage I/II | 54 [62.8] | 78 [53.4] | 132 [56.9] |
Stage III/IV | 32 [37.2] | 68 [46.6] | 100 [43.1] | |
*BMI (Kg/m 2 ) | Median | 21.2 | 21.1 | 21.1 |
(IQR) | [19.2 – 22.2] | [19.4 – 24.5] | [19.4 – 23.6] | |
BMI groups (Kg/m 2 ) | < 18.5 | 12 [14.0] | 24 [16.4] | 36 [15.5] |
≥ 18.5 | 74 [86.1] | 122 [83.6] | 196 [84.5] | |
*CD4 count (cells/uL) | Median | 282 | 288 | 286 |
(IQR) | [205–419] | [193–387] | [199–388] | |
CD4 groups (cells/uL) | < 350.0 | 49 [57.0] | 82 [56.2] | 131 [56.5] |
≥ 350.1 | 29 [33.7] | 41 [28.1] | 70 [30.2] | |
Missing | 8 [9.3] | 23 [15.8] | 31 [13.4] | |
MPR adherence | ≥ 95% (Satisfactory) | 59 [68.6] | 122 [83.6] | 181 [78.0] |
< 95% (Unsatisfactory) | 24 [27.9] | 19 [13.0] | 43 [18.5] | |
 | Missing | 3 [3.5] | 5 [3.4] | 8 [3.5] |